Page 11 - Quotient Sciences News Today

Toronto, ON (PRWEB) January 05, 2023 -- Navigating the small molecule CMC pathway from discovery to the clinic comes with its own set of challenges and

/PRNewswire/ -- Formulation Development Outsourcing Market Research Report by Service, Dosage Form, Application, Region - Global Forecast to 2027 - Cumulative...

/PRNewswire/ -- The "Cytotoxic Drugs and HPAPI Manufacturing Market by Type of Product, Company Size, Scale of Operation, Type of Molecule, Type of Highly...

Integrated Synthesis-to-Clinic Program Will Support HTD1801's Clinical Development and Regulatory Submission Package ROCKVILLE, Md., SHENZHEN, China and NOTTINGHAM, England, Dec. 15, 2022

Nuformix excited by prospects for the remainder of the year

DUBLIN--(BUSINESS WIRE)--The "Bioavailability Enhancement Technologies and Services Market by Drug Class, BCS Classification, Bioavailability Enhancement Approach, Dosage Form and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.This report...

Corporate Update Call to be Held Wednesday, November 16, 2022SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage

NOTTINGHAM, England, Oct. 18, 2022 /PRNewswire/ -- Quotient Sciences, the drug development and manufacturing accelerator, has completed the expansion of its drug substance manufacturing facility

- New patent grant further secures South Ramparts competitive position in next-generation and disruptive investigational drugs for acute pain -NE...

NOTTINGHAM, England, Sept. 29, 2022 /PRNewswire/ -- Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, and Quotient Sciences